Herantis Pharma Plc | Press Release | August 07, 2023 at 10:00:00 EEST
Herantis Pharma Plc, Press Release, 7 August 2023 at 10:00 EEST
Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, today announced that the Herantis team will be attending these scientific conferences in August 2023.
Fluid & Imaging Biomarkers in Neuroscience Summit
Dates: August 22nd – 24th, 2023
Location: Boston, USA
The First Industry Forum for Translational Experts, Neuroscience Drug Sponsors & Biomarker Technology Developers to transform earlier assessment of AD, PD, ALS & MS
Kira Holmström, Head of Biomarker Research at Herantis Pharma, will give an oral presentation with the title: Novel Biomarker Technology in Alzheimer’s, Parkinson’s, ALS and MS.
International Congress of Parkinson’s Disease and Movement Disorders®
Dates: August 27th – 31st, 2023
Location: Copenhagen, Denmark
The International Parkinson and Movement Disorder Society (MDS) gathers thousands of the field's clinicians, researchers, and industry supporters with an interest in the current research and approaches for the diagnosis and treatment of movement disorders on an annual basis at its International Congress of Parkinson's Disease and Movement Disorders®.
If you want 1×1 meetings with Herantis, you can connect with us directly at firstname.lastname@example.org.